{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:09:23Z","timestamp":1792069763279,"version":"4.4.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BU 2562\/2-1"],"award-info":[{"award-number":["BU 2562\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["III45005"],"award-info":[{"award-number":["III45005"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.bone.2013.10.024","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T03:45:53Z","timestamp":1383709553000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients"],"prefix":"10.1016","volume":"59","author":[{"given":"Bj\u00f6rn","family":"Jobke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Milovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.10.024_bb0005","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5years of treatment \u2014 the Fracture Intervention Trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2013.10.024_bb0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older","volume":"58","author":"Boonen","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bone.2013.10.024_bb0020","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.bone.2013.10.024_bb0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","author":"Bauer","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0030","first-page":"265","article-title":"Dose\u2013response relationships for alendronate treatment in osteoporotic elderly women","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.bone.2013.10.024_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.03.017","article-title":"The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover","volume":"37","author":"Borah","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0040","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.bone.2013.10.024_bb0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0050","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4years: the OFELY study","volume":"14","author":"Garnero","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bone.2012.10.016","article-title":"Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls","volume":"52","author":"Schilcher","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0070","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1210\/jc.2012-2590","article-title":"Atypical femur fractures: 81 individual personal histories","volume":"97","author":"Schneider","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.bone.2013.10.024_bb0075","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00432-009-0662-9","article-title":"Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy","volume":"136","author":"Jung","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.024_bb0085","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.bone.2013.10.024_bb0090","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","author":"Shane","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0095","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0100","first-page":"S23","article-title":"Bisphosphonates \u2014 history and experimental basis","volume":"8","author":"Fleisch","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0105","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1210\/endo.141.12.7921","article-title":"In vivo effects of bisphosphonates on the osteoclast mevalonate pathway","volume":"141","author":"Fisher","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2013.10.024_bb0110","first-page":"246","article-title":"Osteoblast and osteoclast cell number and cell-activity in postmenopausal osteoporosis","volume":"12","author":"Gruber","year":"1986","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.bone.2013.10.024_bb0115","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1056\/NEJM198812293192603","article-title":"Diminished rates of bone-formation in normal black adults","volume":"319","author":"Weinstein","year":"1988","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(99)00420-9","article-title":"Apoptosis and osteoporosis","volume":"108","author":"Weinstein","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0125","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy reply","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1359\/jbmr.081225","article-title":"Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate","volume":"24","author":"Cheung","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0135","first-page":"S29","article-title":"Unusual osteoclast morphology in teriparatide-treated patients who have been pretreated with alendronate","volume":"22","author":"Dempster","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0140","first-page":"S414","article-title":"Evidence that high-dose, intermittent ibandronate and zoledronate inhibit osteoclastic bone resorption through a mechanism independent of the mevalonate pathway","volume":"21","author":"Fisher","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0145","first-page":"S87","article-title":"Bisphosphonates improve bone microarchitecture in middle-aged males with osteoporosis by reducing bone turnover: a paired biopsy micro-CT analysis over 38months","volume":"21","author":"Jobke","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMe0806271","article-title":"The deceiving appearances of osteoclasts","volume":"360","author":"Glowacki","year":"2009","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0155","first-page":"1676-1676","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Jobke","year":"2009","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2013.10.024_bb0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00223-011-9500-6","article-title":"Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18months","volume":"89","author":"Jobke","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00313028009060080","article-title":"Quantitative bone histology: a new method","volume":"12","author":"Dunstan","year":"1980","journal-title":"Pathology"},{"key":"10.1016\/j.bone.2013.10.024_bb0170","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1016\/j.actbio.2010.07.019","article-title":"Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: matrix incorporation of strontium is accompanied by changes in mineralization and microstructure","volume":"6","author":"Busse","year":"2010","journal-title":"Acta Biomater"},{"key":"10.1016\/j.bone.2013.10.024_bb0175","doi-asserted-by":"crossref","first-page":"e23638","DOI":"10.1371\/journal.pone.0023638","article-title":"Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment","volume":"6","author":"Jobke","year":"2011","journal-title":"PLoS one"},{"key":"10.1016\/j.bone.2013.10.024_bb0180","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0190","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Investig"},{"key":"10.1016\/j.bone.2013.10.024_bb0195","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ki.1985.49","article-title":"Osteoclast enlargement in endstage renal disease","volume":"27","author":"Kaye","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02555791","article-title":"Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma","volume":"48","author":"Chappard","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0205","series-title":"Handbook of histology methods for bone and cartilage","first-page":"35","article-title":"Cell structure and biology of bone and cartilage","author":"Walsh","year":"2003"},{"key":"10.1016\/j.bone.2013.10.024_bb0210","series-title":"Bone pathology","first-page":"1","article-title":"Bone structure, development and bone biology","author":"Safadi","year":"2009"},{"key":"10.1016\/j.bone.2013.10.024_bb0215","first-page":"S343","article-title":"Atypical osteoclast phenotype after long-term alendronate therapy for osteoporosis: a paired bone biopsies report","volume":"23","author":"Dion","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0220","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bone.2013.10.024_bb0225","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bone.2013.10.024_bb0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/8756-3282(91)90001-Y","article-title":"Effects of ethane-1-hydroxy-1, 1-diphosphonate on cell-differentiation, and proteoglycan and calcium-metabolism, in the proximal tibia of young-rats","volume":"12","author":"Katoh","year":"1991","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0235","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02010363","article-title":"Ethane-1-hydroxy-1,1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei","volume":"22","author":"Miller","year":"1977","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02408548","article-title":"Influence of a diphosphonate on the cellular aspect of young bone tissue","volume":"32","author":"Plasmans","year":"1980","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02546397","article-title":"Alteration of osteoclast morphology by diphosphonates in bone organ-culture","volume":"20","author":"Rowe","year":"1976","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0250","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00003086-198205000-00044","article-title":"The effect of long-term low-dose diphosphonate treatment on rat bone","author":"Evans","year":"1982","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0255","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/endo-97-2-283","article-title":"Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in rat","volume":"97","author":"Thompson","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2013.10.024_bb0260","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/8756-3282(93)90179-E","article-title":"Histomorphometry of how ships lacunae formed invivo and invitro \u2014 depths and volumes measured by scanning electron and confocal microscopy","volume":"14","author":"Jones","year":"1993","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0265","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00185977","article-title":"The relationship between the number of nuclei of an osteoclast and its resorptive capability invitro","volume":"186","author":"Piper","year":"1992","journal-title":"Anat Embryol"},{"key":"10.1016\/j.bone.2013.10.024_bb0270","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/8756-3282(91)90017-D","article-title":"RNA-synthesis in isolated rat osteoclasts \u2014 inhibitory effect of calcitonin","volume":"12","author":"Zheng","year":"1991","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF00316291","article-title":"Effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) on the resorptive function of osteoclasts of known nuclear number","volume":"54","author":"Piper","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0280","first-page":"109","article-title":"The cellular mechanism of action of bisphosphonates","volume":"17","author":"Hughes","year":"1991","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0285","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2013.10.024_bb0290","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(99)00197-0","article-title":"Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment","volume":"25","author":"Ito","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0295","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00223-009-9315-x","article-title":"Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone","volume":"86","author":"Allen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.10.024_bb0300","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/jbmr.070109","article-title":"Are nonresorbing osteoclasts sources of bone anabolic activity?","volume":"22","author":"Karsdal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0305","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/8756-3282(96)00201-3","article-title":"High bone turnover is associated with low bone mass in both pre- and postmenopausal women","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0310","first-page":"1","article-title":"Bisphosphonates for prevention of postmenopausal osteoporosis","volume":"49","author":"Ravn","year":"2002","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.bone.2013.10.024_bb0315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(03)00168-6","article-title":"Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis","volume":"33","author":"Ravn","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0320","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0325","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0330","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0340","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.bone.2007.01.014","article-title":"Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities","volume":"40","author":"Shyu","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.024_bb0345","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000057436","article-title":"In vivo morphologic changes in the rat osteoclast induced by gallium nitrate: the result of toxicity or other effects?","volume":"25","author":"Gruber","year":"1999","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.bone.2013.10.024_bb0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/03008200802412462","article-title":"Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest","volume":"50","author":"Jobke","year":"2009","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0355","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrrheum.2009.87","article-title":"Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges","volume":"5","author":"Jain","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bone.2013.10.024_bb0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0221-8747(81)90027-8","article-title":"Malignant osteopetrosis \u2014 a disease of abnormal osteoclast proliferation","volume":"3","author":"Teitelbaum","year":"1981","journal-title":"Metab Bone Dis Relat Res"},{"key":"10.1016\/j.bone.2013.10.024_bb0365","series-title":"The physiological and cellular basis of metabolic bone disease","author":"Rasmussen","year":"1974"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213004365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213004365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:38:05Z","timestamp":1762659485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213004365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":73,"alternative-id":["S8756328213004365"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.10.024","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2013.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}